Episode Details
Back to Episodes
Pharmaceutical Executive Daily: SanegeneBio's $1.5 Billion License Agreement with Genentech
Published 3 months, 2 weeks ago
Description
In today’s Pharmaceutical Executive Daily, a new a is expected to evolve in 2026, the FDA rejects AstraZeneca’s application for a subcutaneous indication of Saphnelo, and SanegeneBio enters a $1 billion global licensing agreement with Genentech focused on RNAi development.